OBJECTIVES: The aim of this network meta-analysis was to compare the safety of tofacitinib to biological DMARDs for treatment of rheumatoid arthritis in patient with inadequate response to methotrexate. METHODS: We performed an overview of systematic reviews that evaluated biological DMARDs or tofacitinib for treatment of rheumatoid arthritis patients with inadequate response to methotrexate. The searching was carried out using the database of MEDLINE, EMBASE, Lilacs, COCHRANE, DARE and HTA restrictive to systematic review published in the last five years.  The strategy of search was the similar to guideline of rheumatoid arthritis of the Ministry of Health of Colombia. Two researchers selected independently  the studies and extracted the data. La risk of bias of systematic review was assessed with AMSTAR and ISPOR tools. The clinical trials were evaluated with The Cochrane Collaboration's tool for assessing risk of bias